Skip to content
Life Sciences Series A Founded 2016

Seed

Developer of synbiotics for simulating gut microbiome

📍 Los Angeles, United States · Microbiome Therapeutics

Funding snapshot

Last roundSeries A
Amount$41M
Date21 April 2021

About

Developer synbiotics for simulating the gut microbiome. The company metabolomic sequencing and has developed a proprietary screening platform for the screening of host mechanistic pathways. The company claims that the probiotics developed to contain the strains having GRAS and/or QPS (Qualified Presumption of Safety) status. The strains have shown improvements in multiple markers of gastrointestinal health, cardiovascular health, and dermatological health.

Latest news

No articles yet.

Raising like Seed?

Analyze your pitch deck before your next raise.

Analyze My Deck →